LifeSci Advisors Initiates Coverage of Brainstorm Cell Therapeutics

LifeSci Advisors Initiates Coverage of Brainstorm Cell Therapeutics 
Positive Phase I/II Results of NurOwn(TM) Cell Therapy for ALS
Presented at AAN; Phase II Trial Set to Begin at Top US Clinical
Sites: Massachusetts General Hospital, UMass Medical Center, and the
Mayo Clinic; Available for Download at
www.lifesciadvisors.com/clients/brainstorm/ 
NEW YORK, NY -- (Marketwired) -- 04/30/13 --  LifeSci Advisors, LLC,
a leading provider of investment research and investor relations
services in the life sciences sector, today announced that it has
initiated coverage of BrainStorm Cell Therapeutics Inc. (OTCQB:
BCLI), a biotechnology company with a unique approach to treating
debilitating neurodegenerative diseases. Positive Phase I/II safety
and efficacy results were presented in March 2013 for the Company's
stem cell technology as a treatment for amyotrophic lateral sclerosis
(ALS). BrainStorm's presentation was specifically chosen for
expedited release in the Emerging Science Session at the American
Academy of Neurology conference. A new Phase IIa study was initiated
in Israel in December 2012 and a second Phase II trial is slated to
begin after IND approval in late 2013 at three top US clinical sites,
Massachusetts General Hospital, UMass Medical Center, and the Mayo
Clinic. 
"ALS is a complex and difficult disease to treat, and there is a
great need for new therapies to address the underlying disease
pathology," said Andrew I. McDonald, Ph.D., Founding Partner at
LifeSci Advisors. "BrainStorm has presented promising early safety
and efficacy data for their NurOwn(TM) stem cell therapy, which
delivers neurotrophic factors directly to the patient's compromised
nervous system, and this may prove to be a revolutionary treatment
for ALS."  
The Phase I/II trial met the primary endpoints of safety and
efficacy. No serious treatment related adverse events were reported
from the 12 patients enrolled, and 50% of the patients reported no
adverse events at all. The study was an interventional,
non-randomized trial to monitor safety and tolerability of the NurOwn
technology in patients with ALS. Efficacy was measured by changes in
the rate of Amyotrophic Lateral Sclerosis Functional Rating
Scale-Revised (ALSFRS-R) decline and rate of forced vital capacity
(FVC) decline when comparing the 3 months pre-treatment with the 6
months post-treatment. Significant decreases were reported in the
rate of ALSFRS-R decline (p=0.0013) and FVC decline (p < 0.0001) in
the intrathecal (IT) transplanted patients. These results indicate a
trend toward possible stabilization of the disease.  
NurOwn is a novel stem cell technology that BrainStorm has developed
using bone marrow-derived mesenchymal stem cells (MSC) harvested from
the patient receiving the treatment. These autologous cells are
differentiated into neuron-supportive cells that secrete neurotrophic
factors (NTF) such as glial-derived neurotrophic factor and
brain-derived neurotrophic factor, thus they are referred to as
"MSC-NTF" cells, or NurOwn. Autologous adult stem cell therapy is
free of the immune-related issues associated with allogeneic
approaches that use cells from donors, as well as the ethical issues
that are raised with the use of embryonic stem cells. 
In a 25 page Initiation Report by LifeSci Advisors, we explain
BrainStorm's technology and development plans for the NurOwn
technology. The report provides a deep look into the scientific
rationale underpinning the ALS development program, competing
products and development programs, and examines the patient
population and market opportunity for ALS.  
Dr. McDonald's full Initiation Report is available to download at no
cost at the LifeSci Advisors website, www.lifesciadvisors.com. In
addition to this Initiation Report, LifeSci Advisors will also
provide ongoing coverage and event-based research updates on the
Company as developments occur.  
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald,
an industry veteran with more than 15 years of healthcare industry
experience. Prior to co-founding LSA, Dr. McDonald was the Senior
Biotechnology Analyst at Great Point Partners, a leading health care
investment firm with over $500 million under management. Before Great
Point, he was Co-Head of Healthcare Research and Lead Biotechnology
Analyst at ThinkEquity Partners, a boutique investment banking firm
focused on growth companies. Dr. McDonald holds a Ph.D. in organic
chemistry from the University of California, Irvine, and, earlier in
his career, worked as a medicinal chemist at both Pfizer and
Cytokinetics. 
About LifeSci Advisors: 
LifeSci Advisors (LSA) is a leading research firm and communications
consultancy dedicated to the life sciences industry. The firm
provides strategic counsel, customized marketing communications,
comprehensive research reports and investor relations services to
companies that specialize in the discovery, development and
commercialization of drugs, drug delivery systems, medical devices
and diagnostics. To learn more about LSA, visit the company's
website, www.lifesciadvisors.com.  
Important Disclosures: 
The research report described in this press release is not intended
as an offering, recommendation, or a solicitation of an offer to buy
or sell securities. The securities discussed in LSA research reports
may be unsuitable for some investors depending on their specific
investment objectives, financial status, risk profile, or particular
needs. Investors should consider LSA reports as only a single factor
in making their investment decisions and should not rely solely on
these reports in evaluating whether or not to buy or sell the
securities of the subject company. LifeSci Advisors has been
compensated by the company that is the subject of the report
described and future research reports, investor relations services,
and general consulting services. Please read each report's full
disclosures and analyst background on the LSA website,
www.lifesciadvisors.com, before investing. LifeSci Advisors is not a
registered investment adviser or broker-dealer. 
Forward-looking statements: 
This press release contains forward-looking statements subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. These forward-looking statements
represent LSA's judgment as of the date of this release. LifeSci
Advisors disclaims, however, any intent or obligation to update these
forward-looking statements. 
Media Contact:
Michael Rice
Phone: (646) 597-6979
Email: mrice@lifesciadvisors.com  
BrainStorm Cell Therapeutics Contact:
Alon Natanson
CEO
Phone: +972-3-9236384
info@brainstorm-cell.com 
 
 
Press spacebar to pause and continue. Press esc to stop.